Exclusive: Angitia, a Bain-backed musculoskeletal biotech, raises $120M for...
Angitia Biopharmaceuticals, a California and China biotech developing musculoskeletal biologics, has closed a $120 million Series C led by Bain Capital Life Sciences, the drug developer exclusively...
View ArticleGenetic medicine startups Chroma, Nvelop merge into nChroma
What started as two CEOs eating tacos and talking biotech led to a merger and a new company. The epigenetic editing startup Chroma Medicine and the delivery specialist Nvelop Therapeutics said...
View ArticleThe Endpoints 100 Survey: Biotech industry braces for Trump 2.0
Big changes are afoot at the FDA in the wake of Donald Trump’s reelection, and there’s considerable anxiety in senior biotech ranks that an upheaval in the agency could trigger both an exodus of...
View Article#SABCS24: Lilly’s oral SERD makes strides in breast cancer with Phase 3 data
Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or death among patients with mutated estrogen receptor genes, but not in all...
View ArticleAcelyrin says goodbye to the drug that got it a $540M IPO in 2023
Acelyrin is officially ending development of an experimental medicine it referred to as a "diamond in the rough" and that served as the foundation for one of the
View Article#ASH24: Gene editing companies seek safer, less grueling conditioning methods...
SAN DIEGO — New and experimental gene therapies made with blood stem cells rely on the same grueling, decades-old methods for a process called conditioning that’s used for bone marrow transplants. It’s...
View ArticleBenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal
Plus, news about NewAmsterdam, Rocket, ImmunityBio, CG Oncology, Spruce Biosciences, Pharming, Veradermics, Noema Pharma, Ambrosia Biosciences, EsoBiotec, Cellectar Biosciences and Hepion:...
View ArticleRelay Therapeutics plans pivotal trial in second-line breast cancer for 2025
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα inhibitor in breast cancer. In the Phase 1/2 trial, 64 patients with...
View ArticlePost-Hoc: What insurance CEO's killing says about US health anger
Years ago when I was visiting Arizona, Congresswoman Gabby Giffords was shot in the head. Giffords had been greeting constituents at a Tucson shopping mall, and I was riding my bike by the complex as ...
View ArticleCandel soars on prostate cancer data despite unclear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending its share price {$CADL} up around 60% even as the same treatment flunked a...
View ArticleNIH halts enrollment in trial for SIGA's mpox antiviral after disappointing data
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National Institute of Allergy and Infectious Diseases announced this week. SIGA’s...
View ArticleDrugs are approved and available faster in US than most of EU, data show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA Institute for Human Data Science. The difference can be attributed in part ...
View ArticleRFK Jr. lobbied against vaccine EUAs. At HHS, he could undo them
Robert F. Kennedy Jr., President-elect Donald Trump's choice to lead the Department of Health and Human Services, would have the ability to quickly act on his efforts two years ago to halt use of Covid...
View ArticleLilly to study obesity drugs in addiction, and is considering cognitive...
With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is what they'll try and treat next with the drugs. For Eli Lilly, one answer is...
View ArticleLonza looks to depart capsule and health ingredients as it undergoes restructure
Only six months into the role, Lonza’s new CEO Wolfgang Wienand is already looking to make his mark. Lonza said Thursday it is planning to exit the capsules and health ingredients market as the Swiss ...
View ArticleCorcept’s ALS drug fails to improve function in Phase 2 study
It’s been a tough few months for Corcept Therapeutics. In October, the company’s lead pipeline candidate missed the primary endpoint in a Phase 3 Cushing’s syndrome trial. Now, its only neurology asset...
View ArticleHealthcare veteran Glen Tullman thinks AI implementation will define health...
While there’s already plenty of AI in healthcare that focuses on administrative tasks on the back end, it’s time for AI in health consumer-facing products to shine in the year ahead, Glen Tullman told...
View ArticlePleno raises $25M for multiomics testing, names new CEO
Pleno has raised an additional $25 million in private funding to advance its tests that detect biological targets for drug research and diagnostics. The company uses what it calls hypercoding, which...
View Article